Researcher Profile

Researcher Profile

Seema Naik, MD

Seema Naik, MD

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma

Research Interests

  • Transplants
  • Burkitt Lymphoma
  • Survival
  • Acute Myeloid Leukemia
  • Cell Transplantation
  • Hematopoietic Stem Cell Transplantation
  • Neoplasms
  • Bone Marrow
  • Tissue Donors
  • Allogeneic Cells
  • Proxy
  • Quality of Life

Clinical Trials

bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine Pre-conditioning followed by Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
The Effects of a Prehabilitation Exercise Program in Adults Receiving a Hematopoietic Stem Cell Transplant
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Burkitt Lymphoma: A Retrospective Review of Treatment and Outcomes
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Phase III study of daratumumab/rHuPH20 (NSC- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC Study)
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
A Multi-Institutional Retrospective Study of Patient Characteristics, Treatment Patterns and Outcomes in Older Patients with Primary Central Nervous System Lymphoma
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications


Olszewski, AJ, Jakobsen, LH, Collins, GP, Cwynarski, K, Bachanova, V, Blum, KA, Boughan, KM, Bower, M, Dalla Pria, A, Danilov, A, David, KA, Diefenbach, C, Ellin, F, Epperla, N, Farooq, U, Feldman, TA, Gerrie, AS, Jagadeesh, D, Kamdar, M, Karmali, R, Kassam, S, Kenkre, VP, Khan, N, Kim, SH, Klein, AK, Lossos, IS, Lunning, MA, Martin, P, Martinez-Calle, N, Montoto, S, Naik, S, Palmisiano, N, Peace, D, Phillips, EH, Phillips, TJ, Portell, CA, Reddy, N, Santarsieri, A, Sarraf Yazdy, M, Smeland, KB, Smith, SE, Smith, SD, Sundaram, S, Zayac, AS, Zhang, XY, Zhu, C, Cheah, CY, El-Galaly, TC & Evens, AM 2021, 'Burkitt Lymphoma International Prognostic Index', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 10, pp. 1129-1138.
Evens, AM, Danilov, A, Jagadeesh, D, Sperling, A, Kim, SH, Vaca, R, Wei, C, Rector, D, Sundaram, S, Reddy, N, Lin, Y, Farooq, U, D'Angelo, C, Bond, DA, Berg, S, Churnetski, MC, Godara, A, Khan, N, Choi, YK, Yazdy, M, Rabinovich, E, Varma, G, Karmali, R, Mian, A, Savani, M, Burkart, M, Martin, P, Ren, A, Chauhan, A, Diefenbach, C, Straker-Edwards, A, Klein, AK, Blum, KA, Boughan, KM, Smith, SE, Haverkos, BM, Orellana-Noia, VM, Kenkre, VP, Zayac, A, Ramdial, J, Maliske, SM, Epperla, N, Venugopal, P, Feldman, TA, Smith, SD, Stadnik, A, David, KA, Naik, S, Lossos, IS, Lunning, MA, Caimi, P, Kamdar, M, Palmisiano, N, Bachanova, V, Portell, CA, Phillips, T, Olszewski, AJ & Alderuccio, JP 2021, 'Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers', Blood, vol. 137, no. 3, pp. 374-386.
Alderuccio, JP, Olszewski, AJ, Evens, AM, Collins, GP, Danilov, AV, Bower, M, Jagadeesh, D, Zhu, C, Sperling, A, Kim, SH, Vaca, R, Wei, C, Sundaram, S, Reddy, N, Pria, AD, D'Angelo, C, Farooq, U, Bond, DA, Berg, S, Churnetski, MC, Godara, A, Khan, N, Choi, YK, Kassam, S, Yazdy, M, Rabinovich, E, Post, FA, Varma, G, Karmali, R, Burkart, M, Martin, P, Ren, A, Chauhan, A, Diefenbach, C, Straker-Edwards, A, Klein, A, Blum, KA, Boughan, KM, Mian, A, Haverkos, BM, Orellana-Noia, VM, Kenkre, VP, Zayac, A, Maliske, SM, Epperla, N, Caimi, P, Smith, SE, Kamdar, M, Venugopal, P, Feldman, TA, Rector, D, Smith, SD, Stadnik, A, Portell, CA, Lin, Y, Naik, S, Montoto, S, Lossos, IS & Cwynarski, K 2021, 'HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis', Blood Advances, vol. 5, no. 14, pp. 2852-2862.
Shah, N, Rakszawski, K, Nickolich, M, Ehmann, C, Wirk, B, Naik, S, Rybka, W, Zheng, H, Mierski, J, Silar, B, Mackey, G, Greiner, R, Brown, V, Claxton, D, Mineishi, S & Minagawa, K 2021, 'Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion', Annals of Hematology, vol. 100, no. 10, pp. 2585-2592.
Zayac, AS, Evens, AM, Danilov, A, Smith, SD, Jagadeesh, D, Leslie, LA, Wei, C, Kim, SH, Naik, S, Sundaram, S, Reddy, N, Farooq, U, Kenkre, VP, Epperla, N, Blum, KA, Khan, N, Singh, D, Alderuccio, JP, Godara, A, Yazdy, MS, Diefenbach, C, Rabinovich, E, Varma, G, Karmali, R, Shao, Y, Trabolsi, A, Burkart, M, Martin, P, Stettner, S, Chauhan, A, Choi, YK, Straker-Edwards, A, Klein, A, Churnetski, MC, Boughan, KM, Berg, S, Haverkos, BM, Orellana-Noia, VM, D'Angelo, C, Bond, DA, Maliske, SM, Vaca, R, Magarelli, G, Sperling, A, Gordon, MJ, David, KA, Savani, M, Caimi, P, Kamdar, M, Lunning, MA, Palmisiano, N, Venugopal, P, Portell, CA, Bachanova, V, Phillips, T, Lossos, IS & Olszewski, AJ 2021, 'Outcomes of Burkitt lymphoma with central nervous system involvement: Evidence from a large multicenter cohort study', Haematologica, vol. 106, no. 7, pp. 1932-1942.
Gvozdjan, K, Casey, H, Mowery, C, Kumer, L, Fisher, C, Tyler, J, Bayerl, MG, Malysz, J, Naik, S, Rybka, W, Ehmann, C, Claxton, D, Mineishi, S, Baker, M, Hong, Z & Shike, H 2021, 'Unexpected Short-Tandem-Repeat Patterns in Post-Transplant Chimerism Testing: Investigation of 3 Cases with Help from Forensic Science', Laboratory Medicine, vol. 51, no. 6, pp. 635-641.


Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50.


Kilari, D, D'Souza, A, Fraser, R, Qayed, M, Davila, O, Agrawal, V, Diaz, MA, Chhabra, S, Cerny, J, Copelan, E, Farhadfar, N, Freytes, CO, Gale, RP, Ganguly, S, Hildebrandt, GC, Holmberg, L, Kamble, RT, Kapoor, P, Lazarus, H, Lee, C, Murthy, HS, Naik, S, Nishihori, T, Saad, A, Savani, BN, Seo, S, Warwick, A, Wirk, B, Yared, JA, Nieto, Y & Hari, P 2019, 'Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades', Biology of Blood and Marrow Transplantation, vol. 25, no. 6, pp. 1099-1106.
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684.
Naik, S, Riches, M, Hari, P, Kim, S, Chen, M, Bachier, C, Shaughnessy, P, Hill, J, Ljungman, P, Battiwalla, M, Chhabra, S, Daly, A, Storek, J, Ustun, C, Diaz, MA, Cerny, J, Beitinjaneh, A, Yared, J, Brown, V, Page, K, Dahi, PB, Ganguly, S, Seo, S, Chao, N, Freytes, CO, Saad, A, Savani, BN, Woo Ahn, K, Boeckh, M, Heslop, HE, Lazarus, HM, Auletta, JJ & Kamble, RT 2019, 'Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study', Transplant Infectious Disease, vol. 21, no. 5, e13145.


Naik, S 2018, Burkitt’s lymphoma: Etioloy, pathology, prognosis and treatment. in Advances in Health and Disease. vol. 4, Nova Science Publishers, Inc., pp. 173-194.
Rakszawski, K, Miki, K, Claxton, D, Wagner Jr., H, Shike, H, Mineishi, S & Naik, S 2018, 'Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML', International journal of hematology, vol. 108, no. 3, pp. 348-350.
Buchbinder, D, Kelly, DL, Duarte, RF, Auletta, JJ, Bhatt, N, Byrne, M, Defilipp, Z, Gabriel, M, Mahindra, A, Norkin, M, Schoemans, H, Shah, AJ, Ahmed, I, Atsuta, Y, Basak, GW, Beattie, S, Bhella, S, Bredeson, C, Bunin, N, Dalal, J, Daly, A, Gajewski, J, Gale, RP, Galvin, J, Hamadani, M, Hayashi, RJ, Adekola, K, Law, J, Lee, CJ, Liesveld, J, Malone, AK, Nagler, A, Naik, S, Nishihori, T, Parsons, SK, Scherwath, A, Schofield, HL, Soiffer, R, Szer, J, Twist, I, Warwick, AB, Wirk, BM, Yi, J, Battiwalla, M, Flowers, MDE, Savani, B & Shaw, BE 2018, 'Neurocognitive dysfunction in hematopoietic cell transplant recipients: Expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT', Bone Marrow Transplantation, vol. 53, no. 5, pp. 535-555.
Wang, L, Jia, B, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, RJ & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)